Curvebeam AI Ltd Q1 FY27 Investor Presentation
Key points
- Five HiRise devices sold in Q1 FY27, marking the strongest Q1 sales result
- U.S. FDA 510(k) clearance for Bone Mineral Density (BMD) for multidetector CT (MDCT)
- HiRise received regulatory clearance in China, triggering a A$1.0 million payment
- A$7.35m raised through capital raisings, reducing annualized cash-related OpEx to $15m
- Q1 FY27 closed with a cash balance of A$5.83m, with 4.3 quarters of cash available
Full summary
Curvebeam AI Ltd's Q1 FY27 presentation highlighted significant sales achievements with five HiRise devices sold, marking the strongest Q1 sales result to date. The company received U.S. FDA 510(k) clearance for Bone Mineral Density (BMD) for multidetector CT (MDCT) and regulatory clearance in China, triggering a A$1.0 million payment. Additionally, the company raised a total of A$7.35 million through capital raisings, reducing annualized cash-related operating expenses to approximately $15 million. The quarter closed with a cash balance of A$5.83 million, providing 4.3 quarters of cash availability.
Summary generated by a large language model. Please interpret with care.